Navigation Links
Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
Date:6/8/2009

Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints

RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of as yet unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA), held in New Orleans, LA, from June 5 to 9, 2009. Data from Sangamo's SB-509-601 and SB-509-701A Phase 2 clinical trials demonstrated that SB-509 treatment resulted in statistically significant and clinically relevant improvements in subjects with moderate and severe DN as compared to placebo. SB-509 was well-tolerated in both multi-dose studies.

"We have learned a great deal from these data, which demonstrate positive activity of SB-509 in multiple clinically relevant measurements of nerve health," stated Dale Ando, M.D., Sangamo's Vice President of Therapeutic Development and Chief Medical Officer. "Data from our Phase 1 and both Phase 2 clinical trials have shown us that the dual angiogenic and neurotrophic effects of SB-509 are most effective in the later stages of DN when both diabetic microvascular disease and metabolic neuropathy are evident. The statistically significant improvement in SB-509-treated subjects across multiple independent clinical endpoints for DN has enabled definition of a responder group and is particularly encouraging for future trials in this patient population."

"SB-509 is the first drug candidate of its type designed to harness the body's own regenerative potential to address DN, a significant complication for diabetic patients," stated Alan Lewis, Ph.D., President and Chief
'/>"/>

SOURCE Sangamo
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
2. Sangamo BioSciences Reports First Quarter 2009 Financial Results
3. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. BD Biosciences Launches New Cell Analyzer for Complex Multicolor Experiments in Disease and Drug Development Research
6. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
8. Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
9. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
10. Pressure BioSciences, Inc. Provides Corporate Update
11. BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... New York, NY (PRWEB) March 26, 2015 ... year to raise awareness of Parkinson’s disease and funds ... (APDA) purpose to Ease the Burden – Find the ... for registration and will take place in more than ... Phoenix, Rhode Island, New Jersey, San Antonio, Minnesota, Seattle, ...
(Date:3/26/2015)... 2015 In preparation for the 2016 ... founded by Samir Becic, has issued “report cards” ... health and fitness, as well as their promotion of ... includes Sen. Ted Cruz, who has officially announced his ... other politicians who have shown interest in running for ...
(Date:3/26/2015)... CT (PRWEB) March 26, 2015 CRN ... State Capitol Building to help celebrate the achievement of ... groundbreaking employment program serving some 500 people. , The ... The WorkPlace in partnership with the Connecticut ... and prepare long-term unemployed workers and place them at ...
(Date:3/26/2015)... Los Lunas, N.M., resident Lyndsi Alderete never ... year, when she attended a pageant and had an ... a debilitating disease of the lungs that affects the ... failure. The disease turned the Alderete’s world upside down ... pageant to raise awareness about her daughter’s disease. ...
(Date:3/26/2015)... 26, 2015 The beauty industry united ... a man who revolutionized the business of beauty education. ... Passage; founder of Pivot Point International, Inc. Passage’s wife ... of Leo. Held at the Art Institute of Chicago, ... of industry and media leaders and served as the ...
Breaking Medicine News(10 mins):Health News:American Parkinson Disease Association 2015 Optimism Walk Season Launches Nationwide 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:CRN International Shows Support For Groundbreaking Connecticut Program To Aid The Unemployed 2Health News:Albuquerque Area Mom Enters Mrs. New Mexico Pageant to Help Fight Pulmonary Hypertension 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 3
... Point Action Plan on infectious waste control during a ... Monday,s Washington Times (link below), Emergency Preparedness ... issues, such as SARS, have highlighted the vulnerability our ... the area of operational sustainability in a crisis. ...
... Increase in Free Water ClearanceTOKYO and PRINCETON, N.J., ... and Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) ... Administration (FDA) has approved SAMSCA(TM) (tolvaptan) as the ... of patients with clinically significant hypervolemic and euvolemic ...
... Experiences of Denton Regional ... DALLAS, May 21 T-System, Inc., the leading provider of ... care centers, today announced that its Emergency Department Information System ... entitled "ED Information Systems: A Guideline For Successful Implementation" in ...
... the region,s most prominent business organization, today applauded Governor ... report in Atlanta, Georgia. Greater Baltimore Committee President ... process has been of great value to the bioscience ... appreciated by the business community. He is the ...
... 17 states have won awards in the "Fight the Bite" ... Prevention and the DEET Education Program. Started in 2007, ... that encourage children and adults to protect against mosquito and ... of the winning posters are at www.fightthebitecontest.org ...
... May 21 For the second year in a row, ... donate blood through the Red Cross by joining Red ... Cross Racing is a program designed to increase the ... donate. Participants of this program can get points for a ...
Cached Medicine News:Health News:Coalition Calls on Secretary of Health to Make Hospital Emergency Preparedness a Priority 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 3Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 4Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 5Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 6Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 7Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 8Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 9Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 2Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 3Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 2Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3
(Date:3/26/2015)... LAKES, N.J. , March 26, 2015  Becton, ... today that it will commence offers to exchange all ... issued by CareFusion Corporation, a wholly owned subsidiary of ... described in the table below. A Registration Statement on ... of the New Notes was filed with the Securities ...
(Date:3/26/2015)... BUENA, N.J. , March 26, 2015 ... New Jersey based specialty generic pharmaceutical company, ... drug application (ANDA) to the U.S. Food and Drug ... number of ANDA submissions now pending at the FDA ... and CEO of the Company, commented, "On March 2, ...
(Date:3/26/2015)... 2015  Imagine a loved relative suffering from cancer ... the drugs are too expensive. The Austrian Centre of ... to reduce production costs of highly valued drugs significantly. ... the mercy of pathogens or cancer cells. Therapeutic antibodies ... for controlling autoimmune diseases such as multiple sclerosis. According ...
Breaking Medicine Technology:Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2World's First Method for Continuous Purification of Valuable Antibodies 2
... Alternatives International, Inc. ("NAI") (NASDAQ: NAII ), ... supplements, announced today that on February 6 it filed ... Inc. in U.S. District Court for the District of ... 8,067,381 ("the ,381 patent"), entitled "Methods and compositions for ...
... Feb. 14, 2012  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... call and live webcast on Monday, February 27, 2011 at ... will provide a business update and review fourth quarter and ... and press release may be accessed from the Investors section ...
Cached Medicine Technology:Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc. 2Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc. 3
... German Craftsmanship have produced the ... world. Ocutek® now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Vertical punch designed to create a 1.5mm clean cylindrical hole. Rotatable for convenient positioning. Flat Handle. Overall length 87mm....
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
Medicine Products: